{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.52","upperLimit":"18.24","value":"7.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"PFS estimate will be calculated using the Kaplan-Meier method. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesion","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 12 courses and then every 4 weeks for an additional 8 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning week 3, patients undergo 3 fractions of stereotactic body radiation therapy every other day in the absence of disease progression or unacceptable toxicity.\n\nNivolumab: Given IV\n\nIpilimumab: Given IV\n\nStereotactic Body Radiation Therapy: Undergo SBRT","id":"OG000","title":"Treatment (Nivolumab, Ipilimumab, SBRT)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the date of study enrollment, until disease progression or death, assessed up to 4 years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}